Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: To develop and validate algorithms for predicting 30-day fatal and nonfatal opioid-related overdose using statewide data sources including prescription drug monitoring program data, Hospital Discharge Data System data, and Tennessee (TN) vital records. Current overdose prevention efforts in TN rely on descriptive and retrospective analyses without prognostication.
Materials And Methods: Study data included 3 041 668 TN patients with 71 479 191 controlled substance prescriptions from 2012 to 2017. Statewide data and socioeconomic indicators were used to train, ensemble, and calibrate 10 nonparametric "weak learner" models. Validation was performed using area under the receiver operating curve (AUROC), area under the precision recall curve, risk concentration, and Spiegelhalter z-test statistic.
Results: Within 30 days, 2574 fatal overdoses occurred after 4912 prescriptions (0.0069%) and 8455 nonfatal overdoses occurred after 19 460 prescriptions (0.027%). Discrimination and calibration improved after ensembling (AUROC: 0.79-0.83; Spiegelhalter P value: 0-.12). Risk concentration captured 47-52% of cases in the top quantiles of predicted probabilities.
Discussion: Partitioning and ensembling enabled all study data to be used given computational limits and helped mediate case imbalance. Predicting risk at the prescription level can aggregate risk to the patient, provider, pharmacy, county, and regional levels. Implementing these models into Tennessee Department of Health systems might enable more granular risk quantification. Prospective validation with more recent data is needed.
Conclusion: Predicting opioid-related overdose risk at statewide scales remains difficult and models like these, which required a partnership between an academic institution and state health agency to develop, may complement traditional epidemiological methods of risk identification and inform public health decisions.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714265 | PMC |
| http://dx.doi.org/10.1093/jamia/ocab218 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Unlabelled: Policy Points Among patients with chronic noncancer pain, state medical cannabis laws did not impact health care use for opioid use disorder. There were no changes in health care use for opioid overdose attributable to medical cannabis laws. Medical cannabis laws do not appear to lead to reductions in adverse opioid-related outcomes.
View Article and Find Full Text PDFFentanyl-blocking effects of extended-release naltrexone in humans: Three case reports.
J Opioid Manag
September 2025
Retired Addiction Physician and Psychiatrist, London SE1, United Kingdom. ORCID: https://orcid.org/0000-0002-5035-5833.
Despite the contribution of the µ-agonist fentanyl to the United States's opiate overdose epidemic, no human studies specifically address the ability of extended-release preparations of the opiate antagonist naltrexone (NTX) to block fentanyl's life-threatening µ-agonist-mediated respiratory depression. This paper presents three case histories of clinically necessary opiate challenges in opiate-abusing patients implanted with extended-release NTX (ER-NTX). It also reviews the sparse literature and is the first evidence that antagonist blood levels from ER-NTX preparations can completely block the lethal µ-agonist effects of at least 1,000 mcg of intravenous fentanyl.
View Article and Find Full Text PDFHyperalgesia, allodynia, and eventual overdose: The problems with chronic opioid use.
J Opioid Manag
September 2025
HCA Florida Westside Hospital, Davie, Florida. ORCID: https://orcid.org/0009-0006-5906-983X.
Opioids are known to come with some relatively benign side effects, not including their addictive potential. This review will look at some of the side effects that occur when patients, especially chronic pain patients, take opioids chronically. These side effects include both hyperalgesia and allodynia caused by opioids.
View Article and Find Full Text PDFAn individual-level data synthesis of Clinical Trials Network studies to examine the impact of psychosocial treatments for Black people who use cocaine and/or opioids.
Drug Alcohol Depend
August 2025
RTI International, USA.
Objective: Cocaine- and opioid-related overdose deaths have increased among Black people, which makes identifying effective treatments for Black people a high priority. We investigated the comparative effectiveness of behavioral treatments among Black adults who use cocaine and/or opioids.
Methods: Identified multisite randomized clinical trials (RCTs) of behavioral interventions that targeted substance use, had participants who self-identified as Black, and included cocaine use outcome measures from the National Drug Abuse Treatment Clinical Trials Network (CTN) datashare.
Improving Policy Evaluations Of The Opioid Crisis.
Health Aff (Millwood)
September 2025
Bradley D. Stein, RAND Corporation, Pittsburgh, Pennsylvania.
With fatal opioid overdoses rising steadily between 1999 and 2022, researchers have tried to identify effective policy approaches that can stem the tide and mitigate associated harms. However, policy evaluations intended to inform policy choices may muddy the waters, particularly when they generate inconsistent findings. In this article, we discuss a unifying framework and language for presenting analyses using quasi-experimental methods evaluating opioid policies to facilitate greater understanding of similarities and differences across studies.
View Article and Find Full Text PDF